ACB
CDMO

Aristotle Capital Boston’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Aristotle Capital Boston’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-681,999
Closed -$8.42M – 131
2024
Q4 		$8.42M Sell
681,999
-84,341
-11% -$966K 0.31% 97
2024
Q3 		$8.72M Buy
766,340
+52,153
+7% +$523K 0.29% 94
2024
Q2 		$5.1M Sell
714,187
-15,393
-2% -$118K 0.17% 114
2024
Q1 		$4.89M Sell
729,580
-7,161
-1% -$49.3K 0.15% 119
2023
Q4 		$4.79M Buy
736,741
+61,959
+9% +$399K 0.15% 126
2023
Q3 		$6.37M Buy
674,782
+13,797
+2% +$166K 0.21% 118
2023
Q2 		$9.23M Sell
660,985
-6,178
-0.9% -$105K 0.28% 112
2023
Q1 		$12.5M Buy
667,163
+8,778
+1% +$144K 0.39% 94
2022
Q4 		$9.07M Sell
658,385
-13,925
-2% -$213K 0.29% 113
2022
Q3 		$12.9M Sell
672,310
-39,392
-6% -$718K 0.43% 98
2022
Q2 		$10.9M Buy
711,702
+218,674
+44% +$3.23M 0.32% 115
2022
Q1 		$10M Buy
493,028
+35,267
+8% +$718K 0.25% 118
2021
Q4 		$13.4M Sell
457,761
-353
-0.1% -$10.1K 0.31% 117
2021
Q3 		$9.88M Sell
458,114
-2,953
-0.6% -$71.3K 0.23% 122
2021
Q2 		$11.8M Sell
461,067
-17,404
-4% -$372K 0.27% 119
2021
Q1 		$8.72M Buy
478,471
+5,170
+1% +$85.9K 0.19% 127
2020
Q4 		$5.46M Buy
473,301
+358,425
+312% +$3.28M 0.13% 128
2020
Q3 		$875K Buy
+114,876
New +$870K 0.03% 136

Other funds holding CDMO

TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Aristotle Capital Boston's CDMO Position: Q1 2025 in Review

Aristotle Capital Boston sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 681,999 shares — an estimated $8.42M sold.

Aristotle Capital Boston first reported a position in CDMO in Q3 2020 and held it in 18 quarters. The position peaked at $13.4M in Q4 2021. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.

  • Aristotle Capital Boston reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Aristotle Capital Boston sold 681,999 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $8.42M.
  • Aristotle Capital Boston first reported a position in Avid Bioservices, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
  • Aristotle Capital Boston's Avid Bioservices, Inc. Common Stock position peaked at $13.4M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.

Based on Aristotle Capital Boston's 13F filing for Q1 2025, filed 15 May 2025.